Navigation Links
New hope for better treatment for a rising cancer
Date:5/13/2010

Poor diet, too much alcohol, smoking and increasing obesity could be leading to an epidemic of oesophageal and upper stomach cancer, according to a leading UK team of specialists at The University of Nottingham and Nottingham University Hospitals.

The Nottingham Gastro-Oesophageal Cancer Research Group has been carrying out intensive research over the past five years to try to improve the treatment of this cancer. A major part of the research is published today in the British Journal of Cancer. The work has been prompted by a large increase in the incidence of cancer of the oesophagus (gullet) and upper stomach over the past 40 years.

According to Cancer Research UK statistics, rates of oesophageal adenocarcinoma and gastro-oesophageal (GOJ) adenocarcinoma have been increasing in the UK. Since the 1970s the incidence of this cancer has increased by 50 per cent in men and 20 per cent in women. Indeed the reported rates for white men in the UK are now the highest in the world.

Doctors believe changes in diet and lifestyle are the key factors behind the rapid rise in the number of cases. This new research is aimed at providing a better treatment and prognosis for a cancer that is historically not survivable past five years from diagnosis. Current standard treatment for potentially operable cancer consists of a 12 week intensive course of powerful chemotherapy, followed by surgery if the tumour is operable, and then a second 12 week course of chemotherapy. This prolonged, intense course of chemotherapy treatment is potentially toxic, impacts on quality of life and is likely to be beneficial only in those patients who respond to chemotherapy.

The Nottingham-based research using molecular cancer pathology and DNA protein expression techniques on tumour samples from around 250 patients after surgery has shown that only between 40 per cent and 50 per cent of these adenocarcinomas actually respond to the chemotherapy. The research has effectively tested a very promising monitoring test during treatment so that doctors can assess whether and how far the tumour is regressing during chemotherapy. In addition, the research has also identified a promising protein marker involved in DNA repair in cancer cells that predicts resistance to chemotherapy in tumours.

The new information could empower doctors to decide whether to recommend a second course of powerful chemotherapy after surgery. The research also paves the way for wider and more specialised clinical trials for this cancer which will monitor patients in real-time, rather than using past samples, and which could lead to new combinations of chemotherapy, including the new breast cancer drug, Herceptin, which has recently been proven to be effective in gastro-oesophageal cancers.

Dr Srinivasan Madhusudan, Clinical Associate Professor & Consultant in Medical Oncology at Nottingham University Hospitals and the University's School of Molecular Medical Sciences, said: "Recent scientific advances have given real hope for patients with gastro-oesophageal cancers. The Nottingham Upper Gastrointestinal Cancer Group is a multidisciplinary research team consisting of Oncologists, Surgeons, Pathologists and Radiologists. We aim to exploit the 'new science' for patient benefit. This study published online today in the British Journal of Cancer provides evidence that it may be possible to tailor gastro-oesophageal cancer treatments based on 'new' biology. We are planning a larger prospective multicentre study to confirm these findings and we believe will have major clinical impact on how we treat these aggressive tumours in the future."


'/>"/>

Contact: Dr Srinivasan Madhusudan
srinivasan.madhusudan@nottingham.ac.uk
44-011-582-31850
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup
2. Estes Audiology and SERTOMA Club Windcrest Celebrate Better Hearing and Speech Month with Hearing Aid Roundup
3. Better Hearing Institute Joins HHS' Office on Women's Health in Promoting National Women's Health Week and Hearing Health
4. Baby swimmers have better balance
5. Air Quality Better in Northeast, Midwest
6. Better vision ahead for many diabetic retinopathy patients
7. Brown Rice Tied to Better Heart Health in Study
8. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
9. Is patient coding making hospitals appear better than they are?
10. Better vitamin D status could mean better quality of life for seniors
11. Get a Better Shave in Less Time With New Waterless Shave Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from ... will already appear on two major research studies that could impact the health of ... Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold ... Young Investigators: , Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, ... - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih ...
(Date:5/19/2017)... ... 2017 , ... CloSYS products which are marketed as the gentle giants of ... and gum health, which is linked to one’s overall health. Since 1991 when the ... powerful ways in which CloSYS products immediately helped eliminate bad breath as well as ...
(Date:5/18/2017)... ... ... Originally launched to market as the EPIK Learning Tab, the highly successful ... of their product line, the company believed it was the right time to create ... be any tablet product sold by EPIK Learning. This year there will be ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology: